US FDA rejects AZ/BMS diabetes drug dapagliflozin
19 January 2012
Sukaina Virji
Please Login to read the full article.
19 January 2012
Sukaina Virji
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA panel rejects BMS/AstraZeneca diabetes drug on cancer, liver injury concerns
- BMS and AZ to look at cardiprotective effect if dapagliflozin approved in diabetes
- Cancer a concern for BMS/AstraZeneca drug, but liver injury could be FDA panel focus
- FDA rejection of Dapagliflozin creates uncertainty for other SGLT-2 inhibitors
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
- Interview: Adimab's Gerngross seeks two sweethearts
- DKSH highlights one-stop benefits as it builds Asia market expansion services
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
